Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SoftOx Solutions AS Director's Dealing 2021

Feb 25, 2021

3747_dirs_2021-02-25_349dfc25-13b7-4e33-8936-0bfd111c3607.html

Director's Dealing

Open in viewer

Opens in your device viewer

SoftOx Solutions AS: The following is reported from primary insider Claus Seeberg

SoftOx Solutions AS: The following is reported from primary insider Claus Seeberg

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the "Company") on 16 February 2021 regarding the commencement of the subscription period in the planned subsequent offering and parallel employee offering, both consisting of an issuance of up to 181,818 new shares in the Company (the "Subsequent Offering") (the "Employee Offering").

Primary insider Claus Seeberg, though his holding company CS Holding AS has committed to subscribe for NOK 293 150 in the Subsequent Offering.

The shares in the Subsequent offering will be allocated by the Board of Directors and issued under a board authorization granted by the Company's general meeting held on 4 January 2021. The shares in the Subsequent Offering will be allocated by the Board of Directors and will be issued in accordance with the resolution made by the Company's general meeting held on 4 January 2021.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS

Kristine Rød, FM of SoftOx Solutions AS

Mail: [email protected]

Mobile: +47 977 59 071

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com